SANTO, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 223
EU - Europa 183
AS - Asia 63
SA - Sud America 1
Totale 470
Nazione #
US - Stati Uniti d'America 222
GB - Regno Unito 52
CN - Cina 47
SE - Svezia 34
IE - Irlanda 24
FR - Francia 16
RU - Federazione Russa 15
DE - Germania 13
SG - Singapore 12
IT - Italia 11
FI - Finlandia 8
UA - Ucraina 4
BE - Belgio 3
JP - Giappone 2
KR - Corea 2
CA - Canada 1
CH - Svizzera 1
CL - Cile 1
CZ - Repubblica Ceca 1
LV - Lettonia 1
Totale 470
Città #
Chandler 53
Southend 49
Dublin 24
Woodbridge 22
Jacksonville 20
Beijing 14
Ann Arbor 12
Ashburn 12
Houston 10
Wilmington 9
Lawrence 8
New York 8
Princeton 8
Singapore 8
Sindelfingen 6
Helsinki 5
Nanjing 4
Brussels 3
Duncan 3
Jinan 3
Ningbo 3
Zhengzhou 3
Dallas 2
Hamburg 2
Hangzhou 2
Los Angeles 2
Nanchang 2
Seattle 2
Seoul 2
Verona 2
Washington 2
Boardman 1
Bologna 1
Changsha 1
Chaoyang 1
Dongguan 1
Fuzhou 1
Hebei 1
Kent 1
Mehlingen 1
Monmouth Junction 1
Napoli 1
Prague 1
Redmond 1
Redwood City 1
Riga 1
Rome 1
Rovereto 1
San Francisco 1
Santiago 1
Taizhou 1
Tianjin 1
Tokyo 1
Toronto 1
Yicheng 1
Totale 329
Nome #
ALK gene copy number in lung cancer: Unspecific polyploidy versus specific amplification visible as double minutes 118
Renal toxicity and osteonecrosis of the jaw in cancer patients treated with bisphosphonates: a long-term retrospective analysis. 106
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 65
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 58
Incidence of Adverse Cutaneous Reactions to Epidermal Growth Factor Receptor Inhibitors in Patients with Non-Small-Cell Lung Cancer 54
Maintenance with lanreotide in small-cell lung cancer expressing somatostatine receptors: A multicenter, randomized, phase 3 trial 39
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors 33
Management of Italian patients with advanced non-small-cell lung cancer after second-line treatment: results of the longitudinal phase of the LIFE observational study 28
Totale 501
Categoria #
all - tutte 2.030
article - articoli 2.030
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.060


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202041 0 0 1 2 7 5 3 1 4 7 5 6
2020/202169 6 9 4 7 4 27 1 1 0 1 7 2
2021/202258 1 9 0 8 10 3 2 1 2 2 6 14
2022/2023149 10 18 14 17 18 40 1 9 19 0 3 0
2023/202473 4 5 6 9 8 18 2 4 0 5 8 4
2024/202523 12 11 0 0 0 0 0 0 0 0 0 0
Totale 501